Genprex, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
GNPX
Genprex, INCGenprex, Inc. files its 10-K, reporting a net loss for 2024 and providing updates on its clinical development programs in oncology and diabetes.
NASDAQ
GNPX
Genprex, INC10-K: Genprex, Inc. Outlines Progress in Gene Therapy Programs and Financial Position in Annual Report
Genprex, Inc.'s annual report details advancements in its oncology and diabetes gene therapy programs, along with recent financial activities including a reverse stock split and registered direct offering.